Atopic dermatitis: the skin barrier and beyond.
Adaptive Immunity
/ drug effects
Asthma
/ drug therapy
Comorbidity
Dermatitis, Atopic
/ drug therapy
Dermatologic Agents
/ pharmacology
Disease Progression
Epidermis
/ drug effects
Food Hypersensitivity
/ drug therapy
Humans
Immunity, Innate
/ drug effects
Permeability
/ drug effects
Randomized Controlled Trials as Topic
Rhinitis, Allergic, Seasonal
/ drug therapy
Risk Factors
Treatment Outcome
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
accepted:
27
06
2018
pubmed:
4
7
2018
medline:
25
2
2020
entrez:
4
7
2018
Statut:
ppublish
Résumé
Atopic dermatitis is the most common chronic inflammatory skin disorder, affecting up to 20% of children and 10% of adults in industrialized countries. This highly debilitating condition poses a considerable burden to both the individual and society at large. The pathophysiology of atopic dermatitis is complex, encompassing both genetic and environmental risk factors. This is a narrative review based on a systematic literature search. Dysregulation of innate and adaptive immunity plays a key role; however, recent epidemiological, genetic and molecular research has focused interest on skin barrier dysfunction as a common precursor and pathological feature. Current understanding of the aetiology of atopic dermatitis highlights disruption of the epidermal barrier leading to increased permeability of the epidermis, pathological inflammation in the skin, and percutaneous sensitization to allergens. Thus, most novel treatment strategies seek to target specific aspects of the skin barrier or cutaneous inflammation. Several studies have also shown promise in preventing atopic dermatitis, such as the early use of emollients in high-risk infants. This may have broader implications in terms of halting the progression to atopic comorbidities including food allergy, hay fever and asthma.
Sections du résumé
BACKGROUND
Atopic dermatitis is the most common chronic inflammatory skin disorder, affecting up to 20% of children and 10% of adults in industrialized countries. This highly debilitating condition poses a considerable burden to both the individual and society at large. The pathophysiology of atopic dermatitis is complex, encompassing both genetic and environmental risk factors.
METHODS
This is a narrative review based on a systematic literature search.
CONCLUSIONS
Dysregulation of innate and adaptive immunity plays a key role; however, recent epidemiological, genetic and molecular research has focused interest on skin barrier dysfunction as a common precursor and pathological feature. Current understanding of the aetiology of atopic dermatitis highlights disruption of the epidermal barrier leading to increased permeability of the epidermis, pathological inflammation in the skin, and percutaneous sensitization to allergens. Thus, most novel treatment strategies seek to target specific aspects of the skin barrier or cutaneous inflammation. Several studies have also shown promise in preventing atopic dermatitis, such as the early use of emollients in high-risk infants. This may have broader implications in terms of halting the progression to atopic comorbidities including food allergy, hay fever and asthma.
Substances chimiques
Dermatologic Agents
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
464-474Subventions
Organisme : Medical Research Council
ID : MR/R001839/1
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2018 British Association of Dermatologists.